Adstiladrin (Nadofaragene Firadenovec-Vncg) Patent Expiration, LOE Window & CMS Spending

Adstiladrin (Nadofaragene Firadenovec-Vncg) by Ferring Pharmac: Off-Patent Genericized (AB Competition), 0 AB generics, $2.4M 2024 CMS Part D & Medicaid spend, and $60,000 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorFerring Pharmac
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$2.4M
2024 Medicare Part D Spend$1.8M
2024 Medicaid Spend$584K
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($60,000 intro WAC)